Characteristics of the study population
| . | Patients (n = 421) . | Controls (n = 409) . | P . |
|---|---|---|---|
| Demographics | |||
| Age, y | 43.2 ± 6.7 | 39.6 ± 7.6 | .001 |
| Female sex, n (%) | 248 (59%) | 265 (65%) | .09 |
| Classic CVD risk factors, n (%) | |||
| Smoking* | 332 (79%) | 209 (51%) | < .001 |
| Hyperlipidemia | 146 (35%) | 15 (4%) | < .001 |
| Hypertension | 119 (28%) | 24 (6%) | < .001 |
| Diabetes mellitus | 30 (7%) | 3 (1%) | < .001 |
| Positive family history | 206 (49%) | 91 (22%) | < .001 |
| BMI | 26.7 ± 4.7 | 25.5 ± 4.3 | < .001 |
| Blood group, n (%) | |||
| O | 187 (44%) | 186 (45%) | .78 |
| Non-O | 234 (56%) | 223 (55%) | |
| Medication, n (%) | |||
| Antihypertensive drugs | 311 (74%) | 18 (4.5%) | < .001 |
| Statins | 344 (82%) | 6 (1.5%) | < .001 |
| Antiplatelet drugs | 404 (96%) | 6 (1.5%) | < .001 |
| Hormone use† | 84 (34%) | 87 (33%) | .80 |
| Cardiovascular index event | |||
| Coronary heart disease, n (%) | 271 (64%) | ||
| Ischemic stroke, n (%) | 150 (36%) | ||
| VWF:Ag (IU/mL) | 1.26 ± 0.53 | 1.09 ± 0.37 | < .001 |
| VWF:CB (IU/mL) | 1.38 ± 0.54 | 1.25 ± 0.42 | < .001 |
| VWF:CB/VWF:Ag ratio | 1.15 ± 0.31 | 1.17 ± 0.25 | .40 |
| . | Patients (n = 421) . | Controls (n = 409) . | P . |
|---|---|---|---|
| Demographics | |||
| Age, y | 43.2 ± 6.7 | 39.6 ± 7.6 | .001 |
| Female sex, n (%) | 248 (59%) | 265 (65%) | .09 |
| Classic CVD risk factors, n (%) | |||
| Smoking* | 332 (79%) | 209 (51%) | < .001 |
| Hyperlipidemia | 146 (35%) | 15 (4%) | < .001 |
| Hypertension | 119 (28%) | 24 (6%) | < .001 |
| Diabetes mellitus | 30 (7%) | 3 (1%) | < .001 |
| Positive family history | 206 (49%) | 91 (22%) | < .001 |
| BMI | 26.7 ± 4.7 | 25.5 ± 4.3 | < .001 |
| Blood group, n (%) | |||
| O | 187 (44%) | 186 (45%) | .78 |
| Non-O | 234 (56%) | 223 (55%) | |
| Medication, n (%) | |||
| Antihypertensive drugs | 311 (74%) | 18 (4.5%) | < .001 |
| Statins | 344 (82%) | 6 (1.5%) | < .001 |
| Antiplatelet drugs | 404 (96%) | 6 (1.5%) | < .001 |
| Hormone use† | 84 (34%) | 87 (33%) | .80 |
| Cardiovascular index event | |||
| Coronary heart disease, n (%) | 271 (64%) | ||
| Ischemic stroke, n (%) | 150 (36%) | ||
| VWF:Ag (IU/mL) | 1.26 ± 0.53 | 1.09 ± 0.37 | < .001 |
| VWF:CB (IU/mL) | 1.38 ± 0.54 | 1.25 ± 0.42 | < .001 |
| VWF:CB/VWF:Ag ratio | 1.15 ± 0.31 | 1.17 ± 0.25 | .40 |